Dealing with patient variability in PK & PD is an important task during drug development. The covariates defining such variabilities are not easy to find and current practices involve phenotyping or genotyping for known target proteins among other individual attributes. The talk introduces the audience to Liquid Biopsy (LB) for PK & PD targets and summarises the Status of LB for ADMET targets in liver before describing some current debates on pros and cons of this approach.
Following the presentations, attendees are expected:
- To Understand the Ongoing Debates over the Use of Liquid Biopsy - To Distinguish between Tissue-Based RNA Assays vs Cell-Free Assays in Exosomes Floating in Plasma - To Recognize the Temporal Changes in Tissue RNA vs he Stable Pool in Plasma
Learning Objectives:
Upon completion, participants will be able to:
Understand the Ongoing Debates over the Use of Liquid Biopsy
Upon completion, participants will be able to:
To Distinguish between Tissue-Based RNA Assays vs Cell-Free Assays in Exosomes Floating in Plasma
Upon completion, participants will be able to:
To Recognize the Temporal Changes in Tissue RNA vs he Stable Pool in Plasma
